EXACT Sciences Corporation Unveils Latest Presentation on Advanced Cancer Diagnostics and New Test Launches

Reuters

2025/09/23

EXACT Sciences Corporation Unveils Latest Presentation on Advanced Cancer Diagnostics and New Test Launches

EXACT Sciences Corporation has shared its latest corporate presentation, highlighting its role as a global leader in advanced cancer diagnostics with a focus on expanding its capabilities. The company successfully launched three new advanced cancer tests in 2025: Cologuard Plus for colon cancer screening in March, Oncodetect for molecular residual disease in April, and Cancerguard for multi-cancer screening in September. These tests target substantial total addressable markets of $18 billion, $15 billion, and $25 billion respectively. The company reported $811 million in total revenue for the second quarter of 2025, reflecting a 16% year-over-year increase, alongside an adjusted EBITDA of $138 million, up 26% year-over-year. With over 7,000 global team members, 200,000+ ordering providers each quarter, and nine R&D centers and labs, EXACT Sciences continues to deliver over 1.3 million test results in the second quarter of 2025. The company's proprietary scientific platform aims to detect cancer earlier and accurately, supported by its robust commercial engine and ExactNexus technology platform. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569753200"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569753200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569753200?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 06:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569753200","market":"fut","top_or_hot":-1,"title":"EXACT Sciences Corporation Unveils Latest Presentation on Advanced Cancer Diagnostics and New Test Launches","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EXACT Sciences Corporation Unveils Latest Presentation on Advanced Cancer Diagnostics and New Test Launches\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        EXACT Sciences Corporation has shared its latest corporate presentation, highlighting its role as a global leader in advanced cancer diagnostics with a focus on expanding its capabilities. The company successfully launched three new advanced cancer tests in 2025: Cologuard Plus for colon cancer screening in March, Oncodetect for molecular residual disease in April, and Cancerguard for multi-cancer screening in September. These tests target substantial total addressable markets of $18 billion, $15 billion, and $25 billion respectively. The company reported $811 million in total revenue for the second quarter of 2025, reflecting a 16% year-over-year increase, alongside an adjusted EBITDA of $138 million, up 26% year-over-year. With over 7,000 global team members, 200,000+ ordering providers each quarter, and nine R&amp;D centers and labs, EXACT Sciences continues to deliver over 1.3 million test results in the second quarter of 2025. The company's proprietary scientific platform aims to detect cancer earlier and accurately, supported by its robust commercial engine and ExactNexus technology platform. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXACT Sciences Corporation Unveils Latest Presentation on Advanced Cancer Diagnostics and New Test Launches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXACT Sciences Corporation Unveils Latest Presentation on Advanced Cancer Diagnostics and New Test Launches\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-23 06:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EXACT Sciences Corporation Unveils Latest Presentation on Advanced Cancer Diagnostics and New Test Launches\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        EXACT Sciences Corporation has shared its latest corporate presentation, highlighting its role as a global leader in advanced cancer diagnostics with a focus on expanding its capabilities. The company successfully launched three new advanced cancer tests in 2025: Cologuard Plus for colon cancer screening in March, Oncodetect for molecular residual disease in April, and Cancerguard for multi-cancer screening in September. These tests target substantial total addressable markets of $18 billion, $15 billion, and $25 billion respectively. The company reported $811 million in total revenue for the second quarter of 2025, reflecting a 16% year-over-year increase, alongside an adjusted EBITDA of $138 million, up 26% year-over-year. With over 7,000 global team members, 200,000+ ordering providers each quarter, and nine R&amp;D centers and labs, EXACT Sciences continues to deliver over 1.3 million test results in the second quarter of 2025. The company's proprietary scientific platform aims to detect cancer earlier and accurately, supported by its robust commercial engine and ExactNexus technology platform. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日興方舟顛覆性創新基金B SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL3cSyGW:1","article_id":"2569753200","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569753200","pubTimestamp":1758578858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"EXACT Sciences Corporation has shared its latest corporate presentation, highlighting its role as a global leader in advanced cancer diagnostics with a focus on expanding its capabilities. The company successfully launched three new advanced cancer tests in 2025: Cologuard Plus for colon cancer screening in March, Oncodetect for molecular residual disease in April, and Cancerguard for multi-cancer screening in September. These tests target substantial total addressable markets of $18 billion, $15 billion, and $25 billion respectively. The company reported $811 million in total revenue for the second quarter of 2025, reflecting a 16% year-over-year increase, alongside an adjusted EBITDA of $138 million, up 26% year-over-year. With over 7,000 global team members, 200,000+ ordering providers each quarter, and nine R&D centers and labs, EXACT Sciences continues to deliver over 1.3 million test results in the second quarter of 2025. The company's proprietary scientific platform aims to dete","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4588":"碎股","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4585":"ETF&股票定投概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4548":"巴美列捷福持仓","BK4139":"生物科技","EXAS":"精密科学","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD"},"translate_title":"EXACT Sciences Corporation推出有关先进癌症诊断和新测试的最新演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":0.9},"content_text":"EXACT Sciences Corporation Unveils Latest Presentation on Advanced Cancer Diagnostics and New Test Launches\n    \n\n        EXACT Sciences Corporation has shared its latest corporate presentation, highlighting its role as a global leader in advanced cancer diagnostics with a focus on expanding its capabilities. The company successfully launched three new advanced cancer tests in 2025: Cologuard Plus for colon cancer screening in March, Oncodetect for molecular residual disease in April, and Cancerguard for multi-cancer screening in September. These tests target substantial total addressable markets of $18 billion, $15 billion, and $25 billion respectively. The company reported $811 million in total revenue for the second quarter of 2025, reflecting a 16% year-over-year increase, alongside an adjusted EBITDA of $138 million, up 26% year-over-year. With over 7,000 global team members, 200,000+ ordering providers each quarter, and nine R&D centers and labs, EXACT Sciences continues to deliver over 1.3 million test results in the second quarter of 2025. The company's proprietary scientific platform aims to detect cancer earlier and accurately, supported by its robust commercial engine and ExactNexus technology platform. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}